EP0823423B1 — 1,4-disubstituted piperidine derivatives
Assigned to MSD KK · Expires 2004-06-16 · 22y expired
What this patent protects
Novel 1,4-disubstituted piperidine derivatives represented by general formula (I) and pharmaceutically acceptable salts thereof, wherein Ar represents phenyl wherein one or two arbitrary hydrogen atoms on its ring may be substituted by substituent(s) selected from the group consi…
USPTO Abstract
Novel 1,4-disubstituted piperidine derivatives represented by general formula (I) and pharmaceutically acceptable salts thereof, wherein Ar represents phenyl wherein one or two arbitrary hydrogen atoms on its ring may be substituted by substituent(s) selected from the group consisting of halogeno and lower alkyl or an aromatic 5- or 6-membered heterocycle having one or two heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; R<1> represents C3-6 cycloalkyl or C3-6 cycloalkenyl; R<2> represents saturated or unsaturated aliphatic C5-15 hydrocarbon group; and X represents O or NH. The compounds have a selective antagonism against the muscarine M3 receptor and a high safety with little side effect. Thus they are useful in the treatment or prevention of respiratory diseases such as asthma, chronic respiratory obstruction and pulmonary fibrosis, urological diseases accompanied with urination disorders such as frequent urination, urgency of micturition and urinary incontinence and digestive diseases such as convulsion or motion hyperenergia of the digestive tracts and irritable large intestine. <CHEM>
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.